Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
13.07
+0.38 (2.96%)
At close: Oct 9, 2026, 4:00 PM EDT
13.12
+0.05 (0.42%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Bioventus Employees
Bioventus had 950 employees as of June 27, 2026. The number of employees did not change compared to the same quarter last year. That makes Bioventus the 15,278th largest employer in the world and 2,212th in the United States.
Employees
950
Change
n/a
Growth
n/a
Revenue / Employee
$612,472
Profits / Employee
$57,331
Market Cap
1.10B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 27, 2026 | 950 | 0 | - |
| Mar 28, 2026 | 940 | 10 | 1.08% |
| Dec 31, 2025 | 930 | 0 | - |
| Sep 27, 2025 | 950 | -80 | -7.77% |
| Jun 28, 2025 | 950 | -80 | -7.77% |
| Mar 29, 2025 | 930 | -65 | -6.53% |
| Dec 31, 2024 | 930 | -40 | -4.12% |
| Sep 28, 2024 | 1,030 | 60 | 6.19% |
| Jun 29, 2024 | 1,030 | 80 | 8.42% |
| Mar 30, 2024 | 995 | -45 | -4.33% |
| Dec 31, 2023 | 970 | -150 | -13.39% |
| Sep 30, 2023 | 970 | -190 | -16.38% |
| Jul 1, 2023 | 950 | -210 | -18.10% |
| Apr 1, 2023 | 1,040 | -110 | -9.57% |
| Dec 31, 2022 | 1,120 | -80 | -6.67% |
| Oct 1, 2022 | 1,160 | 260 | 28.89% |
| Jul 2, 2022 | 1,160 | 260 | 28.89% |
| Apr 2, 2022 | 1,150 | 250 | 27.78% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 2, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 3, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 3, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 26, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 27, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 2, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Enovis | 7,802 |
| QuidelOrtho | 6,500 |
| Integra LifeSciences Holdings | 4,427 |
| Lumexa Imaging Holdings | 4,335 |
| CONMED | 3,900 |
| Tandem Diabetes Care | 2,500 |
| Artivion | 1,800 |
| PROCEPT BioRobotics | 888 |
BVS News
- 7 weeks ago - Bioventus price target raised to $19 from $15 at Canaccord - TheFly
- 2 months ago - Bioventus price target raised to $18 from $16 at Craig-Hallum - TheFly
- 2 months ago - Bioventus price target raised to $18 from $14 at Barrington - TheFly
- 2 months ago - Bioventus reports Q2 EPS 22c, consensus 22c - TheFly
- 2 months ago - Bioventus backs FY26 adjusted EPS view 75c-79c, consensus 78c - TheFly
- 2 months ago - Bioventus initiates review of strategic alternatives - TheFly
- 2 months ago - Bioventus Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Bioventus Earnings release: Q2 2026 - Filings